Chemotherapy then immunotherapy plus surgery for advanced bladder cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have urothelial cancer (bladder, upper urinary tract, or urethra), confirmed by tissue testing.
- Your cancer is locally advanced (stage cT4 or with certain lymph node involvement), and there is no distant spread seen on scans.
- After 3–4 cycles of chemotherapy with cisplatin or carboplatin plus gemcitabine, your cancer is stable or controlled (not progressing).
- You are healthy enough for treatment: performance status 0–2, and blood/organ tests are adequate (bone marrow, kidneys, and liver).
- You must be willing and fit enough to have radical surgery removing the tumor plus a lymph node template.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a maintenance drug called avelumab can help keep metastatic bladder cancer from growing after patients have already responded to two prior treatments. It is for patients who had a specific sequence of therapies and whose cancer is stable after second-line chemotherapy.
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.